Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.

Guo L, Zhang B, Xue X, Zhang X, Cai H, Jiang H, Zhang L, Jin P, Wang X, Cheng Z, Zhang S, Geng J and 10 more

Show all authors

Guo Y, Hu H, Ma Q, Li L, Du H, Han-Zhang H, Xue F, Deng H, Qian L, Yang W

Nature17 Dec 2025Cited by 13 (Europe PMC)

PMID41407860DOI10.1038/s41586-025-10031-zPepBankPUB-41407860

Publisher page PubMedAsk about this study

Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, more participants on mazdutide 4 mg or 6 mg than on dulaglutide reached HbA1c below 7.0% with at least 5% weight loss at week 28 (both P < 0.0001).
In plain wordsIn Chinese adults with type 2 diabetes, more people on mazdutide than on dulaglutide reached both the HbA1c goal and at least 5% weight loss.
Peptide
Mazdutide
Outcome
IncreaseComposite end point: HbA1c below 7.0% with body-weight reduction of at least 5% at week 28
Study
n = 731
Comparator
Dulaglutide 1.5 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
4 mg and 6 mg · 28 weeksAs given in this study (human).
Source sentences
Summary
Moreover, significantly more participants who received mazdutide 4 mg or 6 mg reached the composite end point of HbA_1c < 7.0% with a body-weight reduction of at least 5% at week 28 (both P < 0.0001), compared with those who received dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 731 participants with T2D were randomized 1:1:1 to receive 4 mg mazdutide, 6 mg mazdutide or 1.5 mg dulaglutide for 28 weeks.
Report a problemFND-4140786005
02HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes, diarrhoea was among the most common treatment-emergent adverse events with mazdutide.
In plain wordsIn Chinese adults with type 2 diabetes, diarrhoea was one of the most common side effects of mazdutide.
Peptide
Mazdutide
Outcome
Direction not reportedDiarrhoea
Study
n = 731
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
4 mg and 6 mg · 28 weeksAs given in this study (human).
Source sentences
Summary
The most common treatment-emergent adverse events were diarrhoea, nausea and vomiting.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 731 participants with T2D were randomized 1:1:1 to receive 4 mg mazdutide, 6 mg mazdutide or 1.5 mg dulaglutide for 28 weeks.
Report a problemFND-4140786006
03HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes, nausea was among the most common treatment-emergent adverse events with mazdutide.
In plain wordsIn Chinese adults with type 2 diabetes, nausea was one of the most common side effects of mazdutide.
Peptide
Mazdutide
Outcome
Direction not reportedNausea
Study
n = 731
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
4 mg and 6 mg · 28 weeksAs given in this study (human).
Source sentences
Summary
The most common treatment-emergent adverse events were diarrhoea, nausea and vomiting.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 731 participants with T2D were randomized 1:1:1 to receive 4 mg mazdutide, 6 mg mazdutide or 1.5 mg dulaglutide for 28 weeks.
Report a problemFND-4140786007
04HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes, vomiting was among the most common treatment-emergent adverse events with mazdutide.
In plain wordsIn Chinese adults with type 2 diabetes, vomiting was one of the most common side effects of mazdutide.
Peptide
Mazdutide
Outcome
Direction not reportedVomiting
Study
n = 731
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
4 mg and 6 mg · 28 weeksAs given in this study (human).
Source sentences
Summary
The most common treatment-emergent adverse events were diarrhoea, nausea and vomiting.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 731 participants with T2D were randomized 1:1:1 to receive 4 mg mazdutide, 6 mg mazdutide or 1.5 mg dulaglutide for 28 weeks.
Report a problemFND-4140786008
05HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes, gastrointestinal adverse events were more frequent with mazdutide than with dulaglutide.
In plain wordsIn Chinese adults with type 2 diabetes, stomach and gut side effects were more common with mazdutide than with dulaglutide.
Peptide
Mazdutide
Outcome
IncreaseIncidence of gastrointestinal adverse events
Study
n = 731
Comparator
Dulaglutide 1.5 mg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
4 mg and 6 mg · 28 weeksAs given in this study (human).
Source sentences
Summary
the incidence of gastrointestinal adverse events was higher for mazdutide than for dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 731 participants with T2D were randomized 1:1:1 to receive 4 mg mazdutide, 6 mg mazdutide or 1.5 mg dulaglutide for 28 weeks.
Report a problemFND-4140786009
06HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, mazdutide 4 mg lowered HbA1c more than dulaglutide 1.5 mg at week 28 (treatment difference -0.24%, P = 0.0032).
In plain wordsIn Chinese adults with type 2 diabetes, mazdutide 4 mg lowered HbA1c more than dulaglutide 1.5 mg.
Peptide
Mazdutide
Outcome
DecreaseHbA1c change from baseline to week 28 (4 mg)
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
4 mg · 28 weeksAs given in this study (human).
Measurements
Treatment difference in HbA1c
−0.24%
mazdutide 4 mg vs dulaglutide
Source sentences
Summary
Both doses of mazdutide showed non-inferiority and superiority to the 1.5-mg dose of dulaglutide in terms of the mean change in the diagnostic marker glycated haemoglobin A1c (HbA_1c) from baseline to week 28, with a least-squares mean treatment difference of -0.24% (P = 0.0032) for 4 mg mazdutide
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 731 participants with T2D were randomized 1:1:1 to receive 4 mg mazdutide, 6 mg mazdutide or 1.5 mg dulaglutide for 28 weeks.
Report a problemFND-4140786001
07HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, mazdutide 6 mg lowered HbA1c more than dulaglutide 1.5 mg at week 28 (treatment difference -0.30%, P = 0.0003).
In plain wordsIn Chinese adults with type 2 diabetes, mazdutide 6 mg lowered HbA1c more than dulaglutide 1.5 mg.
Peptide
Mazdutide
Outcome
DecreaseHbA1c change from baseline to week 28 (6 mg)
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
6 mg · 28 weeksAs given in this study (human).
Measurements
Treatment difference in HbA1c
−0.3%
mazdutide 6 mg vs dulaglutide
Source sentences
Summary
mean change in the diagnostic marker glycated haemoglobin A1c (HbA_1c) from baseline to week 28, with a least-squares mean treatment difference of -0.24% (P = 0.0032) for 4 mg mazdutide and -0.30% (P = 0.0003) for 6 mg mazdutide, relative to 1.5 mg dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 731 participants with T2D were randomized 1:1:1 to receive 4 mg mazdutide, 6 mg mazdutide or 1.5 mg dulaglutide for 28 weeks.
Report a problemFND-4140786002
08HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, mazdutide 4 mg reduced body weight more than dulaglutide (treatment difference -3.78%, P < 0.0001).
In plain wordsIn Chinese adults with type 2 diabetes, mazdutide 4 mg lowered body weight more than dulaglutide.
Peptide
Mazdutide
Outcome
DecreaseBody weight change (4 mg)
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
4 mg · 28 weeksAs given in this study (human).
Measurements
Treatment difference in body weight
−3.78%
mazdutide 4 mg vs dulaglutide
Source sentences
Summary
Significantly greater reductions in body weight were achieved with mazdutide than with dulaglutide, with a least-squares mean treatment difference of -3.78% for 4 mg mazdutide and -5.76% for 6 mg mazdutide (both P < 0.0001), relative to dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 731 participants with T2D were randomized 1:1:1 to receive 4 mg mazdutide, 6 mg mazdutide or 1.5 mg dulaglutide for 28 weeks.
Report a problemFND-4140786003
09HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, mazdutide 6 mg reduced body weight more than dulaglutide (treatment difference -5.76%, P < 0.0001).
In plain wordsIn Chinese adults with type 2 diabetes, mazdutide 6 mg lowered body weight more than dulaglutide.
Peptide
Mazdutide
Outcome
DecreaseBody weight change (6 mg)
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
6 mg · 28 weeksAs given in this study (human).
Measurements
Treatment difference in body weight
−5.76%
mazdutide 6 mg vs dulaglutide
Source sentences
Summary
Significantly greater reductions in body weight were achieved with mazdutide than with dulaglutide, with a least-squares mean treatment difference of -3.78% for 4 mg mazdutide and -5.76% for 6 mg mazdutide (both P < 0.0001), relative to dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 731 participants with T2D were randomized 1:1:1 to receive 4 mg mazdutide, 6 mg mazdutide or 1.5 mg dulaglutide for 28 weeks.
Report a problemFND-4140786004
10HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, dulaglutide reduced HbA1c less than mazdutide 4 mg.
In plain wordsIn Chinese adults with diabetes, dulaglutide lowered blood sugar less than mazdutide 4 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c change
Study
n: not reported in source
Comparator
Mazdutide 4 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 28 weeksAs given in this study (human).
Measurements
HbA1c least-squares mean treatment difference
−0.24%
mazdutide 4 mg relative to dulaglutide 1.5 mg, change from baseline to week 28
Source sentences
Summary
with a least-squares mean treatment difference of -0.24% (P = 0.0032) for 4 mg mazdutide and -0.30% (P = 0.0003) for 6 mg mazdutide, relative to 1.5 mg dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 731 participants with T2D were randomized 1:1:1 to receive 4 mg mazdutide, 6 mg mazdutide or 1.5 mg dulaglutide for 28 weeks.
Report a problemFND-4140786010
11HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, dulaglutide reduced HbA1c less than mazdutide 6 mg.
In plain wordsIn Chinese adults with diabetes, dulaglutide lowered blood sugar less than mazdutide 6 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c change
Study
n: not reported in source
Comparator
Mazdutide 6 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 28 weeksAs given in this study (human).
Measurements
HbA1c least-squares mean treatment difference
−0.3%
mazdutide 6 mg relative to dulaglutide 1.5 mg, change from baseline to week 28
Source sentences
Summary
with a least-squares mean treatment difference of -0.24% (P = 0.0032) for 4 mg mazdutide and -0.30% (P = 0.0003) for 6 mg mazdutide, relative to 1.5 mg dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 731 participants with T2D were randomized 1:1:1 to receive 4 mg mazdutide, 6 mg mazdutide or 1.5 mg dulaglutide for 28 weeks.
Report a problemFND-4140786011
12HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, dulaglutide reduced body weight less than mazdutide 4 mg.
In plain wordsIn Chinese adults with diabetes, dulaglutide reduced weight less than mazdutide 4 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseBody weight change
Study
n: not reported in source
Comparator
Mazdutide 4 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg · 28 weeksAs given in this study (human).
Measurements
body weight least-squares mean treatment difference
−3.78%
mazdutide 4 mg relative to dulaglutide 1.5 mg
Source sentences
Summary
Significantly greater reductions in body weight were achieved with mazdutide than with dulaglutide, with a least-squares mean treatment difference of -3.78% for 4 mg mazdutide and -5.76% for 6 mg mazdutide (both P < 0.0001), relative to dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 731 participants with T2D were randomized 1:1:1 to receive 4 mg mazdutide, 6 mg mazdutide or 1.5 mg dulaglutide for 28 weeks.
Report a problemFND-4140786012
13HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, dulaglutide reduced body weight less than mazdutide 6 mg.
In plain wordsIn Chinese adults with diabetes, dulaglutide reduced weight less than mazdutide 6 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseBody weight change
Study
n: not reported in source
Comparator
Mazdutide 6 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg · 28 weeksAs given in this study (human).
Measurements
body weight least-squares mean treatment difference
−5.76%
mazdutide 6 mg relative to dulaglutide 1.5 mg
Source sentences
Summary
Significantly greater reductions in body weight were achieved with mazdutide than with dulaglutide, with a least-squares mean treatment difference of -3.78% for 4 mg mazdutide and -5.76% for 6 mg mazdutide (both P < 0.0001), relative to dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 731 participants with T2D were randomized 1:1:1 to receive 4 mg mazdutide, 6 mg mazdutide or 1.5 mg dulaglutide for 28 weeks.
Report a problemFND-4140786013
14HumanRandomized controlled trialEfficacy outcome
In Chinese adults with diabetes, fewer dulaglutide recipients reached HbA1c <7.0% with at least 5% weight reduction than mazdutide 4 mg recipients.
In plain wordsFewer Chinese adults with diabetes reached the combined blood sugar and weight target with dulaglutide than mazdutide 4 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c and weight composite response
Study
n: not reported in source
Comparator
Mazdutide 4 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 28 weeksAs given in this study (human).
Source sentences
Summary
Moreover, significantly more participants who received mazdutide 4 mg or 6 mg reached the composite end point of HbA_1c < 7.0% with a body-weight reduction of at least 5% at week 28 (both P < 0.0001), compared with those who received dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 731 participants with T2D were randomized 1:1:1 to receive 4 mg mazdutide, 6 mg mazdutide or 1.5 mg dulaglutide for 28 weeks.
Report a problemFND-4140786014
15HumanRandomized controlled trialEfficacy outcome
In Chinese adults with diabetes, fewer dulaglutide recipients reached HbA1c <7.0% with at least 5% weight reduction than mazdutide 6 mg recipients.
In plain wordsFewer Chinese adults with diabetes reached the combined blood sugar and weight target with dulaglutide than mazdutide 6 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c and weight composite response
Study
n: not reported in source
Comparator
Mazdutide 6 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 28 weeksAs given in this study (human).
Source sentences
Summary
Moreover, significantly more participants who received mazdutide 4 mg or 6 mg reached the composite end point of HbA_1c < 7.0% with a body-weight reduction of at least 5% at week 28 (both P < 0.0001), compared with those who received dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 731 participants with T2D were randomized 1:1:1 to receive 4 mg mazdutide, 6 mg mazdutide or 1.5 mg dulaglutide for 28 weeks.
Report a problemFND-4140786015
16HumanRandomized controlled trialSafety outcome
In Chinese participants with type 2 diabetes, gastrointestinal adverse events were less frequent with dulaglutide than mazdutide.
In plain wordsIn Chinese participants with diabetes, gastrointestinal side effects were less frequent with dulaglutide than mazdutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseGastrointestinal adverse events
Study
n: not reported in source
Comparator
Mazdutide 4 mg or 6 mg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.5 mg · 28 weeksAs given in this study (human).
Source sentences
Summary
Mazdutide was generally safe, although the incidence of gastrointestinal adverse events was higher for mazdutide than for dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, 731 participants with T2D were randomized 1:1:1 to receive 4 mg mazdutide, 6 mg mazdutide or 1.5 mg dulaglutide for 28 weeks.
Report a problemFND-4140786016

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 not yet recruiting · 1 completed · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 4NCT07654062

Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)

Shandong Provincial Hospitaln = 150est. Jul 2026 to est. Jul 2029

Prediabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance (Prediabetes)

Trial page ClinicalTrials.govUpdated 17 Jun 2026

CompletedPhase 3NCT05606913

A Study of IBI362 in Participants With Type 2 Diabetes

Innovent Biologics (Suzhou) Co. Ltd.n = 7316 Jan 2023 to 9 Apr 2024

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 23 Aug 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC